Screener
MoonLake Immunotherapeutics MLTX Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 8:55 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001821586-26-000007
| (in thousands, except share and per share data) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses | ||
| Research and development | $(54,515) | $(36,459) |
| General and administrative | (15,509) | (11,026) |
| Total operating expenses | (70,024) | (47,485) |
| Operating loss | (70,024) | (47,485) |
| Interest expense | (2,269) | (18) |
| Other income, net | 3,208 | 7,097 |
| Loss before income tax | (69,085) | (40,406) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is MoonLake Immunotherapeutics's total operating expenses?
- MoonLake Immunotherapeutics (MLTX) reported total operating expenses of $70.02M in Q1 2026.
- How has MoonLake Immunotherapeutics's total operating expenses changed year-over-year?
- MoonLake Immunotherapeutics's total operating expenses increased by 47.5% year-over-year, from $47.49M to $70.02M.
- What is the long-term trend for MoonLake Immunotherapeutics's total operating expenses?
- Over 3 years (2022 to 2025), MoonLake Immunotherapeutics's total operating expenses has grown at a 55.5% compound annual growth rate (CAGR), from $65.06M to $244.84M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about MoonLake Immunotherapeutics's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude